| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Primary Myelofibrosis | 42 | 2023 | 831 | 10.430 |
Why?
|
| Myeloproliferative Disorders | 26 | 2022 | 769 | 4.940 |
Why?
|
| Polycythemia Vera | 14 | 2023 | 238 | 4.380 |
Why?
|
| Janus Kinase 2 | 22 | 2023 | 680 | 3.600 |
Why?
|
| Thrombocythemia, Essential | 11 | 2022 | 162 | 3.530 |
Why?
|
| Pyrazoles | 25 | 2023 | 1479 | 3.340 |
Why?
|
| Janus Kinase Inhibitors | 6 | 2023 | 68 | 2.820 |
Why?
|
| Nitriles | 25 | 2023 | 904 | 2.300 |
Why?
|
| Leukemia, Myeloid, Acute | 35 | 2024 | 6932 | 2.300 |
Why?
|
| Protein Kinase Inhibitors | 28 | 2023 | 4768 | 2.240 |
Why?
|
| Anemia | 9 | 2023 | 690 | 2.190 |
Why?
|
| Thrombocytopenia | 6 | 2023 | 847 | 1.900 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 17 | 2023 | 2393 | 1.730 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 14 | 2024 | 923 | 1.730 |
Why?
|
| Mastocytosis, Systemic | 6 | 2023 | 110 | 1.650 |
Why?
|
| Antineoplastic Agents | 26 | 2023 | 14288 | 1.540 |
Why?
|
| Sulfonamides | 16 | 2024 | 1826 | 1.490 |
Why?
|
| Janus Kinase 1 | 4 | 2019 | 122 | 1.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 34 | 2024 | 15874 | 1.360 |
Why?
|
| Pyrimidines | 25 | 2023 | 3538 | 1.240 |
Why?
|
| Thrombocytosis | 4 | 2023 | 120 | 1.230 |
Why?
|
| Mutation | 29 | 2022 | 15167 | 1.160 |
Why?
|
| Histone Deacetylase Inhibitors | 6 | 2023 | 612 | 1.130 |
Why?
|
| Janus Kinases | 4 | 2021 | 174 | 0.980 |
Why?
|
| Humans | 145 | 2024 | 262248 | 0.940 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 3 | 2021 | 114 | 0.920 |
Why?
|
| Drug Design | 5 | 2017 | 379 | 0.910 |
Why?
|
| Mastocytosis | 2 | 2021 | 21 | 0.840 |
Why?
|
| Boronic Acids | 4 | 2014 | 363 | 0.840 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2019 | 1493 | 0.790 |
Why?
|
| Pyrazines | 4 | 2014 | 495 | 0.780 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2013 | 305 | 0.770 |
Why?
|
| Benzimidazoles | 4 | 2019 | 428 | 0.750 |
Why?
|
| Histone Demethylases | 2 | 2021 | 144 | 0.750 |
Why?
|
| Piperidines | 10 | 2021 | 1053 | 0.700 |
Why?
|
| Flavonoids | 5 | 2018 | 195 | 0.630 |
Why?
|
| Triazines | 4 | 2023 | 117 | 0.620 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2023 | 2982 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 10 | 2021 | 2334 | 0.610 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.600 |
Why?
|
| Blast Crisis | 4 | 2021 | 557 | 0.580 |
Why?
|
| Aged | 61 | 2023 | 70367 | 0.570 |
Why?
|
| Proteasome Inhibitors | 2 | 2014 | 230 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2021 | 481 | 0.530 |
Why?
|
| Aged, 80 and over | 38 | 2023 | 29996 | 0.510 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2021 | 802 | 0.510 |
Why?
|
| Orphan Drug Production | 1 | 2014 | 10 | 0.490 |
Why?
|
| Pyrroles | 4 | 2023 | 584 | 0.490 |
Why?
|
| Middle Aged | 60 | 2024 | 86544 | 0.490 |
Why?
|
| Pteridines | 1 | 2014 | 34 | 0.480 |
Why?
|
| Adult | 51 | 2024 | 78179 | 0.460 |
Why?
|
| Blood Platelet Disorders | 1 | 2013 | 37 | 0.440 |
Why?
|
| Treatment Outcome | 33 | 2023 | 33028 | 0.440 |
Why?
|
| Prognosis | 21 | 2022 | 21737 | 0.430 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2013 | 69 | 0.430 |
Why?
|
| Female | 66 | 2024 | 142293 | 0.420 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2019 | 1093 | 0.410 |
Why?
|
| Receptors, Thrombopoietin | 3 | 2021 | 65 | 0.410 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 3 | 2023 | 426 | 0.410 |
Why?
|
| Bortezomib | 7 | 2020 | 544 | 0.410 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 1083 | 0.410 |
Why?
|
| Antirheumatic Agents | 1 | 2014 | 224 | 0.400 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1350 | 0.390 |
Why?
|
| Signal Transduction | 10 | 2022 | 11972 | 0.390 |
Why?
|
| Polyethylene Glycols | 2 | 2019 | 621 | 0.390 |
Why?
|
| Immunoconjugates | 1 | 2014 | 284 | 0.390 |
Why?
|
| Male | 61 | 2024 | 123338 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2020 | 5183 | 0.380 |
Why?
|
| Hematologic Neoplasms | 3 | 2021 | 1901 | 0.370 |
Why?
|
| Phyllodes Tumor | 1 | 2010 | 62 | 0.360 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 480 | 0.340 |
Why?
|
| Receptors, Fc | 1 | 2009 | 68 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2022 | 2525 | 0.340 |
Why?
|
| STAT Transcription Factors | 2 | 2021 | 79 | 0.340 |
Why?
|
| Thrombopoietin | 1 | 2009 | 77 | 0.340 |
Why?
|
| Splenomegaly | 2 | 2020 | 158 | 0.330 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 3755 | 0.330 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 1122 | 0.330 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2009 | 70 | 0.330 |
Why?
|
| Survival Rate | 13 | 2021 | 12239 | 0.330 |
Why?
|
| Tandem Repeat Sequences | 2 | 2019 | 201 | 0.330 |
Why?
|
| Adenine | 6 | 2023 | 639 | 0.320 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2014 | 1041 | 0.320 |
Why?
|
| Animals | 18 | 2023 | 59489 | 0.310 |
Why?
|
| Leukemia | 2 | 2018 | 1633 | 0.310 |
Why?
|
| Dasatinib | 3 | 2022 | 862 | 0.300 |
Why?
|
| Azacitidine | 6 | 2024 | 1149 | 0.290 |
Why?
|
| Remission Induction | 7 | 2023 | 3584 | 0.280 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2019 | 274 | 0.280 |
Why?
|
| Bone Marrow | 5 | 2022 | 2360 | 0.280 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 2 | 2022 | 505 | 0.280 |
Why?
|
| Quinolines | 1 | 2009 | 383 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 10067 | 0.270 |
Why?
|
| Neoplasms | 7 | 2023 | 15180 | 0.270 |
Why?
|
| DNA Damage | 1 | 2014 | 1947 | 0.270 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 2325 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2021 | 6607 | 0.260 |
Why?
|
| Young Adult | 15 | 2022 | 21494 | 0.260 |
Why?
|
| Triazoles | 2 | 2021 | 618 | 0.260 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2017 | 1759 | 0.260 |
Why?
|
| Genomics | 1 | 2016 | 2744 | 0.260 |
Why?
|
| Cytarabine | 6 | 2023 | 1976 | 0.260 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 305 | 0.260 |
Why?
|
| Thrombosis | 3 | 2023 | 786 | 0.250 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 10021 | 0.250 |
Why?
|
| Philadelphia Chromosome | 3 | 2019 | 792 | 0.240 |
Why?
|
| Daunorubicin | 3 | 2020 | 302 | 0.240 |
Why?
|
| Antifungal Agents | 2 | 2021 | 840 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 5538 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 1557 | 0.230 |
Why?
|
| Idarubicin | 2 | 2023 | 446 | 0.230 |
Why?
|
| Recurrence | 6 | 2021 | 4784 | 0.220 |
Why?
|
| Pyridines | 2 | 2021 | 1243 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 2288 | 0.220 |
Why?
|
| Drug Discovery | 2 | 2017 | 326 | 0.220 |
Why?
|
| Mast Cells | 2 | 2021 | 222 | 0.210 |
Why?
|
| Blood Platelets | 2 | 2018 | 730 | 0.210 |
Why?
|
| Apoptosis | 6 | 2021 | 7601 | 0.210 |
Why?
|
| Serum Amyloid P-Component | 1 | 2022 | 30 | 0.210 |
Why?
|
| Calreticulin | 2 | 2019 | 75 | 0.210 |
Why?
|
| Benzamides | 2 | 2022 | 1834 | 0.210 |
Why?
|
| Leukocytosis | 1 | 2022 | 111 | 0.210 |
Why?
|
| Alleles | 3 | 2019 | 2434 | 0.210 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 8885 | 0.200 |
Why?
|
| Cholestyramine Resin | 1 | 2021 | 17 | 0.200 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 2053 | 0.200 |
Why?
|
| RNA Splicing Factors | 1 | 2022 | 153 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 4945 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 65 | 0.200 |
Why?
|
| Antimetabolites | 1 | 2021 | 69 | 0.190 |
Why?
|
| Retreatment | 3 | 2017 | 453 | 0.190 |
Why?
|
| Mutation Rate | 2 | 2019 | 222 | 0.190 |
Why?
|
| Carrier Proteins | 1 | 2009 | 2022 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 101 | 0.190 |
Why?
|
| Anemia, Sideroblastic | 1 | 2021 | 58 | 0.190 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.190 |
Why?
|
| Bridged-Ring Compounds | 2 | 2020 | 183 | 0.190 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 1397 | 0.190 |
Why?
|
| Goals | 1 | 2022 | 188 | 0.190 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 118 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 2362 | 0.180 |
Why?
|
| Carbamates | 1 | 2020 | 77 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 1250 | 0.180 |
Why?
|
| Wnt-5a Protein | 1 | 2019 | 45 | 0.180 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2019 | 454 | 0.170 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 14913 | 0.170 |
Why?
|
| bcl-X Protein | 2 | 2017 | 196 | 0.170 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 2915 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2021 | 6223 | 0.170 |
Why?
|
| Interferon-alpha | 2 | 2023 | 889 | 0.170 |
Why?
|
| Survival Analysis | 6 | 2020 | 9195 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 526 | 0.160 |
Why?
|
| Age Factors | 2 | 2020 | 5384 | 0.160 |
Why?
|
| Drug Synergism | 2 | 2019 | 1316 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2020 | 177 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3233 | 0.160 |
Why?
|
| Ki-1 Antigen | 1 | 2019 | 182 | 0.160 |
Why?
|
| beta Catenin | 2 | 2020 | 687 | 0.160 |
Why?
|
| Risk Factors | 8 | 2022 | 17622 | 0.160 |
Why?
|
| Leukocyte Count | 2 | 2018 | 683 | 0.160 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2019 | 197 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 54 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 541 | 0.150 |
Why?
|
| Japan | 1 | 2018 | 226 | 0.150 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2017 | 43 | 0.150 |
Why?
|
| Prevalence | 2 | 2023 | 3272 | 0.150 |
Why?
|
| Plateletpheresis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Anaphylaxis | 1 | 2018 | 120 | 0.150 |
Why?
|
| Haptoglobins | 1 | 2017 | 26 | 0.150 |
Why?
|
| Reticulocytes | 1 | 2017 | 54 | 0.150 |
Why?
|
| Hematologic Agents | 1 | 2016 | 13 | 0.150 |
Why?
|
| Europe | 1 | 2019 | 646 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 447 | 0.140 |
Why?
|
| Biomimetics | 1 | 2017 | 35 | 0.140 |
Why?
|
| Disease Progression | 4 | 2021 | 6693 | 0.140 |
Why?
|
| Blood Cell Count | 1 | 2017 | 225 | 0.140 |
Why?
|
| Phosphoproteins | 1 | 2022 | 1151 | 0.140 |
Why?
|
| Medical Oncology | 3 | 2022 | 1424 | 0.140 |
Why?
|
| Casein Kinase II | 1 | 2017 | 69 | 0.140 |
Why?
|
| Immunophenotyping | 2 | 2018 | 1684 | 0.140 |
Why?
|
| Survival | 1 | 2016 | 177 | 0.140 |
Why?
|
| CD5 Antigens | 1 | 2017 | 115 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2021 | 5253 | 0.140 |
Why?
|
| Immunotherapy | 3 | 2019 | 3347 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 2420 | 0.140 |
Why?
|
| Pemetrexed | 1 | 2016 | 102 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 162 | 0.140 |
Why?
|
| Cell Nucleus | 2 | 2018 | 1618 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 135 | 0.140 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 3482 | 0.130 |
Why?
|
| Transcriptome | 2 | 2021 | 1863 | 0.130 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2017 | 183 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 3818 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 479 | 0.130 |
Why?
|
| Rituximab | 2 | 2017 | 1534 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2017 | 437 | 0.130 |
Why?
|
| Retrospective Studies | 13 | 2023 | 38011 | 0.120 |
Why?
|
| Karyotype | 3 | 2020 | 234 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 421 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2021 | 12923 | 0.120 |
Why?
|
| RNA Splicing | 1 | 2016 | 369 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 941 | 0.120 |
Why?
|
| Nitrophenols | 1 | 2014 | 93 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2015 | 477 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2018 | 1667 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2017 | 295 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 2152 | 0.110 |
Why?
|
| Molecular Motor Proteins | 1 | 2013 | 36 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3263 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2018 | 798 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2019 | 3022 | 0.110 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 193 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 581 | 0.110 |
Why?
|
| Myosin Heavy Chains | 1 | 2013 | 129 | 0.110 |
Why?
|
| Imatinib Mesylate | 2 | 2019 | 1665 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 278 | 0.110 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2018 | 719 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 1294 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 87 | 0.110 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10348 | 0.100 |
Why?
|
| Gene Expression | 2 | 2018 | 3563 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 526 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 260 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 367 | 0.100 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2012 | 174 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2014 | 417 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 1295 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2021 | 6129 | 0.100 |
Why?
|
| Patient Safety | 1 | 2017 | 648 | 0.100 |
Why?
|
| Hydroxyurea | 2 | 2023 | 204 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 279 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2017 | 1265 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 2734 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 1439 | 0.090 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 1668 | 0.090 |
Why?
|
| Proteins | 1 | 2019 | 1953 | 0.090 |
Why?
|
| Biomarkers | 5 | 2020 | 5055 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 1435 | 0.090 |
Why?
|
| Mice | 5 | 2023 | 34393 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2059 | 0.090 |
Why?
|
| Sirolimus | 1 | 2014 | 818 | 0.090 |
Why?
|
| Exons | 1 | 2013 | 1325 | 0.090 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2009 | 18 | 0.090 |
Why?
|
| Transplantation, Homologous | 3 | 2021 | 2892 | 0.080 |
Why?
|
| Quality of Life | 3 | 2018 | 4582 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 15709 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2017 | 5598 | 0.080 |
Why?
|
| Staurosporine | 2 | 2019 | 142 | 0.080 |
Why?
|
| Allografts | 2 | 2021 | 656 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 2633 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3550 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 897 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 1307 | 0.080 |
Why?
|
| Propensity Score | 2 | 2022 | 755 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2021 | 666 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2012 | 875 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 4787 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 4745 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2022 | 14561 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 2485 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2013 | 2085 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4043 | 0.070 |
Why?
|
| Shock, Septic | 1 | 2009 | 184 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2028 | 0.070 |
Why?
|
| Mitoxantrone | 2 | 2018 | 217 | 0.070 |
Why?
|
| Piperazines | 2 | 2014 | 2098 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 1974 | 0.070 |
Why?
|
| Platelet Count | 2 | 2018 | 490 | 0.070 |
Why?
|
| DNA Repair | 1 | 2014 | 1870 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 665 | 0.070 |
Why?
|
| Hydroxamic Acids | 2 | 2020 | 444 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 4027 | 0.060 |
Why?
|
| Genotype | 1 | 2013 | 4104 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 754 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5155 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 4386 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4355 | 0.060 |
Why?
|
| Activin Receptors, Type I | 1 | 2023 | 49 | 0.060 |
Why?
|
| Hepcidins | 1 | 2023 | 34 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2017 | 1290 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2018 | 715 | 0.060 |
Why?
|
| Disease Management | 2 | 2020 | 1063 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2022 | 5378 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 2279 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2015 | 337 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2021 | 3080 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2019 | 1340 | 0.050 |
Why?
|
| Protein Binding | 2 | 2019 | 3438 | 0.050 |
Why?
|
| Cladribine | 1 | 2023 | 233 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4563 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2022 | 88 | 0.050 |
Why?
|
| Adolescent | 5 | 2024 | 31239 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 2804 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2023 | 254 | 0.050 |
Why?
|
| Fatigue | 2 | 2018 | 1239 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2021 | 163 | 0.050 |
Why?
|
| Chimerism | 1 | 2021 | 65 | 0.050 |
Why?
|
| Oncogene Fusion | 1 | 2021 | 63 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2009 | 2297 | 0.050 |
Why?
|
| Arthralgia | 1 | 2021 | 95 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2020 | 424 | 0.050 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 41 | 0.050 |
Why?
|
| Consolidation Chemotherapy | 1 | 2020 | 154 | 0.050 |
Why?
|
| Constipation | 1 | 2021 | 178 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2009 | 2519 | 0.040 |
Why?
|
| Hypophosphatemia | 1 | 2019 | 25 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2019 | 55 | 0.040 |
Why?
|
| Acetanilides | 1 | 2018 | 16 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2023 | 483 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2018 | 17 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 113 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 603 | 0.040 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2018 | 61 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 67 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2021 | 835 | 0.040 |
Why?
|
| Proteolysis | 1 | 2020 | 368 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 333 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2019 | 217 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 134 | 0.040 |
Why?
|
| Inflammation | 2 | 2019 | 2514 | 0.040 |
Why?
|
| Candidemia | 1 | 2018 | 60 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 148 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 488 | 0.040 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 189 | 0.040 |
Why?
|
| Platelet Transfusion | 1 | 2018 | 156 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 301 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 784 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 2019 | 258 | 0.040 |
Why?
|
| Thiazoles | 1 | 2021 | 727 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 474 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 464 | 0.040 |
Why?
|
| Depsipeptides | 1 | 2017 | 78 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2017 | 311 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2017 | 202 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 984 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 904 | 0.030 |
Why?
|
| K562 Cells | 1 | 2017 | 339 | 0.030 |
Why?
|
| Pyridones | 1 | 2019 | 350 | 0.030 |
Why?
|
| Vidarabine | 1 | 2021 | 1347 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1046 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2232 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 1236 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 555 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 328 | 0.030 |
Why?
|
| Vincristine | 1 | 2019 | 1508 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 809 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 388 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2017 | 252 | 0.030 |
Why?
|
| Pneumonia | 1 | 2021 | 754 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 13669 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1554 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 9282 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 965 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 767 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 346 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 188 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 1865 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2019 | 1450 | 0.030 |
Why?
|
| Binding Sites | 1 | 2019 | 2170 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 703 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 2431 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 802 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 587 | 0.030 |
Why?
|
| Neutrophils | 1 | 2018 | 834 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2017 | 1642 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2017 | 855 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 425 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 3042 | 0.030 |
Why?
|
| Indoles | 1 | 2019 | 1011 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 673 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2019 | 3005 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5339 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 723 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1957 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2021 | 2671 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2480 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 986 | 0.020 |
Why?
|
| Aging | 1 | 2019 | 1533 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 1367 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3447 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 929 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 5009 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1338 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 4809 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1541 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 11571 | 0.020 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 1215 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 2824 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7218 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 12984 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6255 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 8882 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 16213 | 0.020 |
Why?
|
| United States | 1 | 2019 | 15574 | 0.010 |
Why?
|